Navigation Links
OXiGENE Announces a Poster Presentation Highlighting Results from,its Study of ZYBRETSTAT CA4P in Myopic Macular Degeneration (Study,MMD-213) at the 47th Annual Meeting of the Association of Research,in Vision and Ophthalmology

WALTHAM, Mass.--(BUSINESS WIRE)--May 7, 2007 - OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a clinical-stage biotechnology company developing novel therapeutics to treat cancer and eye diseases, announced today that the results of its Phase II combretastatin A4 phosphate (CA4P) clinical trial in myopic macular degeneration (MMD) was presented at the 47th Annual Meeting of the Association of Research in Vision and Ophthalmology (ARVO) in Fort Lauderdale, FL. The abstract may be viewed at www.arvo.org.

The following are the poster session details: -0-

Poster No.:   1457/B534

Abstract      Phase II Clinical Trial of Intravenous Combretastatin A4

 Title:        Phosphate in Patients With Subfoveal Choroidal

               Neovascular Membranes (CNV) in Pathologic Myopia

Presentation  Monday, May 07, 2007, 8:30 AM -10:15 AM

 Time:

The poster provided additional details from the ZYBRESTAT(TM) CA4P Phase II clinical trial (MMD-213) in Myopic Macular Degeneration, top-line results from which the Company previously announced on February 15, 2007. Based on the positive results from this study, in which 100% of patients met the primary endpoint of maintenance of visual acuity, the Company has held a pre-IND meeting with the FDA regarding topical ophthalmic formulations (eye drops and ocular mini-tabs), is proceeding with development of a topical formulation of ZYBRESTAT(TM), and anticipates filing and IND and initiating clinical studies with the formulation in early 2008.

About the Study (MMD-213):

MMD-213 was a Phase II, double-masked (physician and subject), dose-ranging, multi-center study designed to evaluate the safety and efficacy of intravenous CA4P for treating subfoveal choroidal neovascularization in subjects with pathologic myopia. Subjects were assigned to receive CA4P at doses of 27, 36 or 45 mg/m(2). A total of 23 subjects, 7-8 per arm, were enrolled. All subjects receive
'"/>




Page: 1 2 3

Related medicine technology :

1. OXiGENE Abstracts Published in ASCO Program
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:9/17/2014)... Calif. , Sept. 17, 2014 ... Prostate Vanguard, an awareness campaign to educate men about ... needle biopsies of the prostate. Annually, a million ... gland through the rectum. Multi-parametric MRI (MP-MRI) of the ... prostate cancer (CSPC). Men need to be fully ...
(Date:9/17/2014)... Sept. 17, 2014  Rebiotix Inc. announced this morning that ... product candidate, RBX2660 (microbiota suspension) will be presented in two ... in Philadelphia from October 8-12. ... the poster session on Thursday, October 9, 2014: ... Infection: 60-Day Interim Analysis of the PUNCH-CD Phase 2 Safety ...
(Date:9/17/2014)... SAN JOSE, Calif. , Sept. 17, 2014 /PRNewswire-iReach/ ... a laureate of The Tech Awards 2014, one of ... humanity and spark global change. The Tech Awards, a signature ... Applied Materials, Inc., selected Gradian as one of two laureates ... http://photos.prnewswire.com/prnh/20140917/146680 Gradian equips hospitals around ...
Breaking Medicine Technology:Prostate Cancer Awareness Month - Stop Random Biopsies 2Prostate Cancer Awareness Month - Stop Random Biopsies 3PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 2PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 3PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 4Gradian Health Systems Named A 2014 Laureate of The Tech Awards 2Gradian Health Systems Named A 2014 Laureate of The Tech Awards 3
... New data presented at annual American Transplant Congress ... R. Carreno, MD, and colleagues in,the Departments of ... -,Lawrence Miller School of Medicine have corroborated the ... in recipients of,kidney transplants using a regular laboratory ...
... 2 Medarex, Inc.,(Nasdaq: MEDX ) ... Phase 1,study of MDX-1106 (ONO-4538: development code ... anti-PD-1 antibody. Data presented from patients with,recurrent ... the safety,tolerability and pharmacokinetic profile of single-dose ...
Cached Medicine Technology:University of Miami Team Confirms Value of Monitoring Cell-Mediated Immunity Pre- and Post-Transplant in Management of Kidney Transplant Recipients 2University of Miami Team Confirms Value of Monitoring Cell-Mediated Immunity Pre- and Post-Transplant in Management of Kidney Transplant Recipients 3University of Miami Team Confirms Value of Monitoring Cell-Mediated Immunity Pre- and Post-Transplant in Management of Kidney Transplant Recipients 4Preliminary Data from Ongoing Phase 1 Data of Investigational Anti-PD-1 Antibody Presented at American Society of Clinical Oncology Annual Meeting 2Preliminary Data from Ongoing Phase 1 Data of Investigational Anti-PD-1 Antibody Presented at American Society of Clinical Oncology Annual Meeting 3Preliminary Data from Ongoing Phase 1 Data of Investigational Anti-PD-1 Antibody Presented at American Society of Clinical Oncology Annual Meeting 4
(Date:9/17/2014)... reduce the need for invasive biopsies in patients suffering ... In a new study, researchers developed a math model ... inflammation to interstitial fibrosis, scarring in the kidney ... the only existing way to reach a definitive diagnosis ... could also be used to monitor the effectiveness of ...
(Date:9/17/2014)... shown that most 18-month-olds learn an average of two ... known about how children process information to learn new ... a new study, a University of Missouri researcher has ... and a limit exists as to how many words ... parents enhance their children,s vocabularies and assist speech-language professionals ...
(Date:9/17/2014)... Missouri (PRWEB) September 17, 2014 Mercy ... week, hoisting the building’s final beam into place. Sister ... it made its ascent. (Photos and video of the ... the beam, available here: http://bit.ly/MercyVirtual .) , “The ... high quality medical care to thousands of patients regardless ...
(Date:9/17/2014)... 2014 In a country where 77% ... a regular basis, how can Americans find healthy and ... Hyland’s Stress Challenge , a 5-day interactive journey to ... life. From September 29th – October 3rd, the ... relating to specific topics that promote natural solutions for ...
(Date:9/17/2014)... September 17, 2014 Ticket Down ... tickets for all tour dates. The Disney on ... characters around the United States and across the world to ... year, the 2013 cult-hit Frozen will be showcased in the ... shows, Frozen on Ice. The show will kicked off at ...
Breaking Medicine News(10 mins):Health News:Math model designed to replace invasive kidney biopsy for lupus patients 2Health News:Babies learn words differently as they age, researcher finds 2Health News:Mercy Tops Out World's First Virtual Care Center 2Health News:Stress Less with the Hyland's 5-Day Stress Challenge 2Health News:Frozen on Ice Tickets: Ticket Down Slashes Ticket Prices in Atlanta, Uniondale, Richmond, Philadelphia, Hershey, Nashville, Hampton, Brooklyn, Chicago, Boston & St. Louis 2
... it,s no better than standard treatment, one expert says, ... the indigestion and heartburn that bother many women as ... Indigestion is common during pregnancy, with up to 80 ... reflux, belching and bloating. Symptoms tend to worsen over ...
... - Europe Cosmetiques and Probiox announced today that both ... respect to oxidative stress profiling. Under this agreement, Europe ... and Mexico. , According to Manon Pilon, Founder President ... the leader in the Medical SPA industry, and is ...
... PEMBROKE, Bermuda, June 9 Allied World ... Assurance Company,Holdings, Ltd (NYSE: AWH ), today ... product offered in the United States. The,complimentary service, called ... crisis management resources in the,event of a catastrophe. , ...
... Pharmaceuticals, Inc. (Nasdaq: JAZZ ) announced today ... trial of sodium oxybate (JZP-6) for the treatment of ... Professional Sleep Societies (APSS) 2009 Annual Meeting in Seattle, ... (EULAR) Congress in Copenhagen, Denmark. , , Following ...
... Programs Designed to Address High Risks for New Dialysis Patients ... , DENVER, June 9 DaVita Inc. (NYSE: ... those diagnosed with chronic kidney disease (CKD), today commended Kidney ... Kidney Care (PEAK) campaign. Kidney Care Partners - a ...
... New techniques bring equivalent results without the potential dangers, ... Researchers say they,ve developed new techniques for reducing ... disease. , The use of these radiation-lowering strategies did ... computed tomography angiography (CCTA), an increasingly popular weapon in ...
Cached Medicine News:Health News: Acupuncture May Relieve Heartburn In Pregnancy 2Health News: Acupuncture May Relieve Heartburn In Pregnancy 3Health News:"Alliance between Europe Cosmetiques and Probiox brings new oxydative stress profiling technologies to North America" 2Health News:Allied World U.S. Announces Strategic Response(SM) - Complimentary Service Added to General Liability Lead Umbrella Product 2Health News:Allied World U.S. Announces Strategic Response(SM) - Complimentary Service Added to General Liability Lead Umbrella Product 3Health News:Jazz Pharmaceuticals to Present Data From First Phase III Study of Sodium Oxybate in Patients With Fibromyalgia 2Health News:Jazz Pharmaceuticals to Present Data From First Phase III Study of Sodium Oxybate in Patients With Fibromyalgia 3Health News:Jazz Pharmaceuticals to Present Data From First Phase III Study of Sodium Oxybate in Patients With Fibromyalgia 4Health News:DaVita Commends Kidney Care Partners for Launch of PEAK Campaign 2Health News:DaVita Commends Kidney Care Partners for Launch of PEAK Campaign 3Health News:Reduced-Radiation Heart Scans Don't Compromise on Quality 2
The Becton™ Colles Fracture Plate has proven clinical outcomes and has excellent patient acceptance compared to external fixation. It provides a cost effective treatment option through a simple...
Standard Trephine...
Coronet Vacuum Trephine - All metal, ergonomic design and ultra sharp blade with cross hairs....
Long Handled Trephine...
Medicine Products: